Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

97.48USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$97.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
370,458
52-wk High
$153.80
52-wk Low
$49.20

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -5.12 -- --
ROI: -33.58 1.58 14.38
ROE: -39.86 2.41 16.07

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

20 Apr 2018

BRIEF-Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent

* CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT

03 Apr 2018

BRIEF-Silence Therapeutics Brings Patent Infringement Proceedings Against Alnylam's Patisiran Product

* SAYS BROUGHT PATENT INFRINGEMENT PROCEEDINGS IN PORTUGAL AGAINST ALNYLAM'S PATISIRAN PRODUCT Source text for Eikon: Further company coverage:

03 Apr 2018

Pfizer's rare heart disease drug succeeds in late-stage study

Pfizer Inc's experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

29 Mar 2018

UPDATE 2-Pfizer's rare heart disease drug succeeds in late-stage study

* Brokerage Suntrust estimates sales of $130 mln of drug in 2022

29 Mar 2018

BRIEF-Alnylam Receives European Medicines Agency Prime Designation For Accelerated Assessment Of Lumasiran

* ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

26 Mar 2018

Earnings vs. Estimates